Immunohistological Detection of Small Particles of Echinococcus Species Evaluated
By LabMedica International staff writers Posted on 18 Jan 2021 |

Image: Fluorescence staining of lymph node containing spegs from patients with cystic echinococcosis (Photo courtesy of University of Ulm).
Echinococcosis, also known as Hydatid Disease, is a life-threatening disease in humans that is caused by the larval stages of the tapeworms Echinococcus multilocularis and Echinococcus granulosus s.l. The two main types of this disease are cystic echinococcosis (CE) and alveolar echinococcosis (AE).
Humans are infected as accidental dead-end hosts and are not involved in the perpetuation of the complex life cycle of the tapeworms. CE is the most frequently encountered form of echinococcosis with worldwide prevalence and over one million infected humans. Most but not all human infections occur in the liver. In contrast to AE (over 95% primary lesions in the liver), CE may affect other organ systems such as the lungs. The clinical diagnosis may be delayed in both diseases due to a long asymptomatic interval.
A team of medical scientists at the University of Ulm (Ulm, Germany) tested formalin-fixed paraffin-embedded (FFPE) tissue material of patients with the immunohistochemically approved diagnosis of AE, typical morphology and positive staining with monoclonal antibody mAb Em2G11 and CE typical morphology and no staining with mAb Em2G1, following known criteria. The cohort for testing mAb EmG3 included 360 specimens of 156 patients with AE. Most samples originated from the liver (n = 240). Six samples were fluid specimens like pleural effusion and five cystic fine needle aspirates. Additional, 178 specimens of 77 CE patients were tested, including three fine needle aspirates. Both cohorts included bioptic material in addition to resected specimens. Hematoxylin and eosin (HE), Periodic acid-Schiff (PAS), and Immunohistochemistry (IHC) staining were performed according to standard protocols.
The scientists showed that the mAb EmG3 has a specific staining pattern of the metacestode stadium of E. multilocularis and E. granulosus s.l. while staining of the larval state of E. multilocularis is limited to the mAb Em2G11. They further identified so called “small particles of Echinococcus multilocularis” (spems) and “small particles of Echinococcus granulosus” (spegs) not only in the main lesion of AE and CE, but also in the adjacent tissue and in the vast majority of lymph nodes analyzed draining the main lesion. The lymph nodes with these microparticles are enlarged as compared to a control group.
The authors concluded that immunochemistry with these two antibodies is a valuable adjunct for the final histological diagnosis of AE und CE. The frequent detection of microparticles of E. multilocularis and E. granulosus in lymph nodes of patients with AE and CE argue for a larger interface of interaction of the parasite with the host`s immune system than previously assumed and point to further mechanisms of these infections in humans which may be the basis for immunological reactions in the host. The study was published on December 28, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Ulm
Humans are infected as accidental dead-end hosts and are not involved in the perpetuation of the complex life cycle of the tapeworms. CE is the most frequently encountered form of echinococcosis with worldwide prevalence and over one million infected humans. Most but not all human infections occur in the liver. In contrast to AE (over 95% primary lesions in the liver), CE may affect other organ systems such as the lungs. The clinical diagnosis may be delayed in both diseases due to a long asymptomatic interval.
A team of medical scientists at the University of Ulm (Ulm, Germany) tested formalin-fixed paraffin-embedded (FFPE) tissue material of patients with the immunohistochemically approved diagnosis of AE, typical morphology and positive staining with monoclonal antibody mAb Em2G11 and CE typical morphology and no staining with mAb Em2G1, following known criteria. The cohort for testing mAb EmG3 included 360 specimens of 156 patients with AE. Most samples originated from the liver (n = 240). Six samples were fluid specimens like pleural effusion and five cystic fine needle aspirates. Additional, 178 specimens of 77 CE patients were tested, including three fine needle aspirates. Both cohorts included bioptic material in addition to resected specimens. Hematoxylin and eosin (HE), Periodic acid-Schiff (PAS), and Immunohistochemistry (IHC) staining were performed according to standard protocols.
The scientists showed that the mAb EmG3 has a specific staining pattern of the metacestode stadium of E. multilocularis and E. granulosus s.l. while staining of the larval state of E. multilocularis is limited to the mAb Em2G11. They further identified so called “small particles of Echinococcus multilocularis” (spems) and “small particles of Echinococcus granulosus” (spegs) not only in the main lesion of AE and CE, but also in the adjacent tissue and in the vast majority of lymph nodes analyzed draining the main lesion. The lymph nodes with these microparticles are enlarged as compared to a control group.
The authors concluded that immunochemistry with these two antibodies is a valuable adjunct for the final histological diagnosis of AE und CE. The frequent detection of microparticles of E. multilocularis and E. granulosus in lymph nodes of patients with AE and CE argue for a larger interface of interaction of the parasite with the host`s immune system than previously assumed and point to further mechanisms of these infections in humans which may be the basis for immunological reactions in the host. The study was published on December 28, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Ulm
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more